What Biopharmas Need To Know About Genetic Data Privacy

By Roshni Ghosh, Ph.D. And Keith Noe

Recent advances in genome sequencing technology have attracted the interest of biopharmaceutical companies for the development of personalized medicine or therapeutics for potentially “untreatable” diseases. Ever-expanding databases from large-scale biological experiments, clinical trials, genetic records of individuals from DTC genetic-testing companies, and medical records from patients participating in data collection have enabled computational inference akin to real-world biomedical research.

Such approaches may also enable companies to design more effective treatments for diseases such as cancer, hypercholesterelomia, and diabetes.